Clinical Trials Browser

Phase 3 × Carcinoma, Non-Small-Cell Lung × Ipilimumab × Clear all

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03391869 2025-12-17

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

339 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03520686 2025-10-16

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

1,538 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02864251 2023-09-28

CheckMate722

Phase 3 Completed

367 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03302234 2023-09-26

KEYNOTE-598

Phase 3 Completed

568 enrolled 20 charts

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03048136 2018-04-17

CheckMate 955

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

CheckMate 816

CheckMate 9LA

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

CheckMate 227

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

CheckMate722

KEYNOTE-598

CheckMate 955